Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial of LP-184/STAR-001 in pediatric CNS Cancer

Next Previous
Trial Profile

A clinical trial of LP-184/STAR-001 in pediatric CNS Cancer

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 27 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Irofulven (Primary) ; Spironolactone (Primary)
  • Indications CNS cancer; Rhabdoid tumour
  • Focus Therapeutic Use

Most Recent Events

  • 27 Oct 2025 New trial record
  • 03 Sep 2025 According to the Lantern Pharma Media Release, The planned trial is expected to enroll pediatric patients across multiple sites, with primary endpoints focused on progression-free survival, overall response rate, and quality-of-life measures. with planned trial initiation targeted for Q1 2026.
  • 03 Sep 2025 According to the Lantern Pharma Media Release, company announced the successful completion of a Type C meeting with the U.S. Food and Drug Administration (FDA). The meeting provided critical guidance on the regulatory pathway and trial design for a planned pediatric trial focused on CNS cancers, including Atypical Teratoid Rhabdoid Tumor (ATRT).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top